The FDA and Kratom: The Regulatory Picture in 2026

The relationship between the FDA and kratom is two decades of friction without resolution. The FDA has never approved kratom for any use, considers it an unsafe food additive, and has pressed for scheduling — but kratom remains federally legal, and the practical consequences for buyers are specific and worth knowing. This is where the federal picture stands in 2026.

The FDA’s core positions

• No approval, ever. Kratom is not an approved drug or dietary ingredient. Any vendor marketing it as treating any condition is breaking federal law — the basis for repeated FDA warning letters.
• Import Alert 54-15. Kratom shipments may be detained without physical examination at the US border — a standing enforcement tool that periodically removes foreign inventory.
• Adverse-event and contamination focus. The FDA’s public health warnings centre on contamination (notably the 2018 multistate salmonella outbreak linked to kratom) and on products making opioid-withdrawal or pain-treatment claims. The outbreak story is covered in salmonella and kratom safety.
• Eight-factor analysis. In 2018 the FDA’s scheduling recommendation to the DEA concluded kratom’s alkaloids had opioid-like abuse potential; the DEA declined to schedule after massive public comment — and has not scheduled kratom since.

What changed in 2025–2026: the synthetic turn

The most consequential recent federal action targeted not botanical kratom but semi-synthetic analogs: in 2026 the DEA temporarily scheduled mitragynine pseudoindoxyl, MGM-15 and MGM-16 as Schedule I, and a separate federal process has been reviewing concentrated 7-hydroxymitragynine. State regulators moved first — Florida, Ohio and Tennessee all acted against 7-OH concentrates between 2025 and 2026, as detailed in which states banned kratom. The regulatory target is increasingly potency and synthesis, not the plant itself — a distinction explained in what 7-hydroxymitragynine is.

What this actually means for buyers

1. Federal legality is stable. Botanical kratom and standardized mitragynine products remain legal under federal law; the action is at state level — see kratom laws by state.
2. Claims are the enforcement trigger. Vendors stay legal by making no medical claims — every product page and guide on this site operates under that rule.
3. Contamination is the real safety history. The FDA’s strongest kratom case was a salmonella outbreak — which is a manufacturing and testing failure, exactly what batch lab testing and GMP certification exist to prevent.
4. Watch the 7-OH space. Products with added 7-hydroxymitragynine face the most regulatory risk nationwide. Ours contain none.

The path everyone is watching

Two federal end-states remain possible: scheduling (which the FDA has recommended since 2018) or a national consumer-protection framework resembling the state KCPA model, described in what is the KCPA. Through 2026, Congress has shown more interest in the second path — but nothing has passed, which makes state law the rulebook that actually governs your order.

Related reading

• Kratom laws by state — the rules that actually apply.
• Kratom microbial testing — what prevents the next outbreak.
• Kratom heavy metals testing — the other contamination story.

These statements have not been evaluated by the FDA. Kratom is not intended to diagnose, treat, cure or prevent any disease. Regulatory information current as of late 2026; not legal advice. Adults 21+ only.